Analysts at Stifel Nicolaus Maintained their Past ‘Buy’ rating on Shares Alexion Pharmaceuticals Inc (NASDAQ:ALXN), Set a $245.00 Price Objective

Share

Alexion Pharmaceuticals Inc (NASDAQ:ALXN) Rating Reaffirmed

In analysts note made public on Friday, 11 December, The Buy rating of Alexion Pharmaceuticals Inc (NASDAQ:ALXN) shares was kept steady by Analysts at Stifel Nicolaus, who now has a $245.00 target price per share on the stock. Stifel Nicolaus’s target price per share implies a possible upside of 29.95% from the previous close of the company.

From a total of 15 analysts covering Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) stock, 13 rate it a ”Buy”, 0 a “Sell”, and 4 a ”Hold”. This means that 76% of the ratings are positive. The highest target price is $250 while the lowest target price is $190. The mean of all analyst targets is $218.13 with a 19.61% above today’s ($188.22) stock price. Alexion Pharmaceuticals Inc. was the topic of 9 analyst reports since July 27, 2015 according to the firm StockzIntelligence Inc. Morgan Stanley upgraded shares on October 2 to “Overweight” rating. JP Morgan initiated shares with “Overweight” rating and $249 target share price in a report from a July 27. Vetr upgraded ALXN stock in a recent report from August 12 to “Buy” rating. Finally, Brean Capital maintained the stock with “Buy” rating in a report issued on a July 31.

Approximately 1.37M shares of stock traded hands or 5.38% up from the average. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has risen 15.10% since May 8, 2015 and is uptrending. It has outperformed by 18.11% the S&P500.

The overall sentiment of institutions has decreased to 1.07 in Q2 2015. Its down 0.33, from 1.4 in 2015Q2. The ratio worsened, as 71 institutions have sold all the shares of Alexion Pharmaceuticals, Inc. that they owned while 166 funds have taken shares off the table. 42 funds have purchased shares for the first time while 211 added to their positions. These institutions now hold 233.06 million shares or 6.74% more than the 218.35 million shares they owned in 2015Q2.

The Fund Lamond Capital Partners Llc currently is holding shares equating to 11.7% of its total portfolio in Alexion Pharmaceuticals, Inc. representing a total of 100,000 shares. Another fund,Baker Bros. Advisors Lp, is holding a total of 6.54 million shares equating to 9.45% of their holdings. Additionally, Index Management Solutions Llc has a 145,883 share stake in Alexion Pharmaceuticals, Inc. which represents 8.54% of their total portfolio. The Fund, Lagoda Investment Management L.P., based out of New York, has also built up a stake in the stock, which represents a total of 7.62% of their total portfolio. Finally Blue Jay Capital Management Llc, a fund which is based in the state of California reported a total holdings of 89,884 shares.

Insider activity is a very important aspect to track on any stock. Going back to March 3, 2015, shareholders of Alexion Pharmaceuticals, Inc. have witnessed 0 insider buys, and a total of 10 insider sales equating to a net activity of approximately $5.86 million . Thiel Carsten sold 812 shares worth approximately $137,371. Miller Edward sold 366 shares worth approximately $65,715. O’neill Julie sold 647 shares worth approximately $111,129. Bell Leonard sold 1,050 shares worth approximately $189,105. The company insider Carmichael Clare sold 305 shares worth $51,429.

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The company has a market cap of $42.20 billion. The Firm is focused on the development and commercialization of life-transforming therapeutic products. It has 152.86 P/E ratio. As of June 23, 2015, the Company had eight product candidates in clinical trials for 11 indications.

According to Zacks Investment Research, “Alexion Pharmaceuticals develops pharmaceutical products for the treatment of heart disease, and inflammation, diseases of the immune system and cancer in humans. The company’s lead product candidates are genetically altered antibodies that target specific diseases which arise when the human immune system induces undesired inflammation in the human body. These candidates are designed to block components of the human immune system which cause undesired inflammation while allowing beneficial components of the immune system to remain functional.” Get a free copy of the Zacks research report on Alexion Pharmaceuticals, Inc. (ALXN).

COMMENTS: